What this study adds
Twice-daily (BID) dosing of MR309 provided a plasma PK profile with
less fluctuation than once-daily dosing
A monotonic relationship between MR309 plasma concentration and brain
σ1R occupancy was seen, but 200 mg BID did not achieve 75% σ1R
occupancy required for maximal antinociception in animal models